» Articles » PMID: 38270295

Interaction Between Long Noncoding RNA and MicroRNA in Lung Inflammatory Diseases

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-coding RNAs (ncRNAs) are a group of RNAs that cannot synthesize proteins, but are critical in gene expression regulation. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), the two major family members, are intimately involved in controlling immune response, cell proliferation, apoptosis, differentiation and polarization, and cytokine secretion. Their interactions significantly influence lung inflammatory diseases and could be potential therapeutic targets.

Objectives: The review aims to elucidate the role of ncRNAs, especially the interactions between lncRNA and miRNA in lung diseases, including acute and chronic lung inflammatory diseases, as well as lung cancer. And provide novel insights into disease mechanisms and potential therapeutic methods.

Methods: We conducted a comprehensive review of the latest studies on lncRNA and miRNA in lung inflammatory diseases. Our research involved searching through electronic databases like PubMed, Web of Science, and Scopus.

Results: We explain the fundamental characteristics and functions of miRNA and lncRNA, their potential interaction mechanisms, and summarize the newly explorations on the role of lncRNA and miRNA interactions in lung inflammatory diseases.

Conclusions: Numerous lncRNAs and miRNAs have been found to partipicate in all stages of lung inflammatory diseases. While ncRNA-based therapies have been validated and developed, there remain challenges in developing more stable and effective drugs for clinical use.

Citing Articles

Loc646329 sponges miR-21 to reduce RAS/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC).

Adereh A, Amini P, Fateh A, Faghihkhorasani F, Khdakarim N, Marashi S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39673637 DOI: 10.1007/s00210-024-03671-x.


Interaction between long noncoding RNA and microRNA in lung inflammatory diseases.

Li J, Huang S, Shi L, Chen G, Liu X, Liu M Immun Inflamm Dis. 2024; 12(1):e1129.

PMID: 38270295 PMC: 10777888. DOI: 10.1002/iid3.1129.

References
1.
Fu C, Zhou L, Mi Q, Jiang A . Plasmacytoid Dendritic Cells and Cancer Immunotherapy. Cells. 2022; 11(2). PMC: 8773673. DOI: 10.3390/cells11020222. View

2.
Winkle M, El-Daly S, Fabbri M, Calin G . Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021; 20(8):629-651. PMC: 8212082. DOI: 10.1038/s41573-021-00219-z. View

3.
Xia R, Geng G, Yu X, Xu Z, Guo J, Liu H . LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs. J Immunother Cancer. 2021; 9(8). PMC: 8395365. DOI: 10.1136/jitc-2021-002746. View

4.
Tang H, Gao Y, Li Z, Miao Y, Huang Z, Liu X . The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. Clin Transl Med. 2020; 10(6):e200. PMC: 7548099. DOI: 10.1002/ctm2.200. View

5.
Dai L, Zhang G, Cheng Z, Wang X, Jia L, Jing X . Knockdown of LncRNA MALAT1 contributes to the suppression of inflammatory responses by up-regulating miR-146a in LPS-induced acute lung injury. Connect Tissue Res. 2018; 59(6):581-592. DOI: 10.1080/03008207.2018.1439480. View